RECRUITING

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Conditions

Breast Cancer Gastric Cancer Esophageal Cancer Gastroesophageal Cancer Colorectal Cancer Endometrial Cancer Non-small Cell Lung Cancer Ovarian Cancer Urothelial Carcinoma Salivary Gland Cancer Pancreatic Cancer HER-2 Protein Overexpression JZP598 ZW25 HER2 IHC 3+ Overexpression Solid Tumors

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Official Title

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Quick Facts

Study Start:2024-12-31

Study Completion:2027-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06695845

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Is at least 18 years of age inclusive at the time of signing the informed consent 2. Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required. 3. HER2 overexpression (IHC 3+) via Immunohistochemistry (IHC). 4. All participants must have adequate tumor sample for submission to allow central HER2 testing. 5. Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) 6. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Has a life expectancy of at least 3 months, in the opinion of the investigator. 8. Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met: 1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS. 2. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention. 3. Recovery to no more than Grade 1 or baseline from any acute toxicity associated with the treatment. 9. Adequate organ functions. 10. Females of childbearing potential must have a negative pregnancy test result. 11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.	1. Has known or suspected leptomeningeal disease and/or untreated brain metastasis. 2. Has uncontrolled or significant cardiovascular disease 3. Has ongoing toxicity related to prior cancer therapy 4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals. 5. Has known Human Immunodeficiency Virus (HIV) infection. 6. Has active hepatitis B or C infection. 7. Has an active severe acute respiratory syndrome coronavirus 2 infection. 8. Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab. 9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site. 10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study. 11. Prior treatment with HER2-targeted therapy (Cohort 1 only). 12. Has a history of trauma or major surgery 13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to enrollment. 14. Was treated in a prior clinical study of zanidatamab or received zanidatamab at any time prior to the current study. 15. Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations. 16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion. 17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.

Inclusion Criteria

Exclusion Criteria

1. Is at least 18 years of age inclusive at the time of signing the informed consent
2. Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required.
3. HER2 overexpression (IHC 3+) via Immunohistochemistry (IHC).
4. All participants must have adequate tumor sample for submission to allow central HER2 testing.
5. Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
6. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. Has a life expectancy of at least 3 months, in the opinion of the investigator.
8. Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met:
1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS.
2. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention.
3. Recovery to no more than Grade 1 or baseline from any acute toxicity associated with the treatment.
9. Adequate organ functions.
10. Females of childbearing potential must have a negative pregnancy test result.
11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.

1. Has known or suspected leptomeningeal disease and/or untreated brain metastasis.
2. Has uncontrolled or significant cardiovascular disease
3. Has ongoing toxicity related to prior cancer therapy
4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals.
5. Has known Human Immunodeficiency Virus (HIV) infection.
6. Has active hepatitis B or C infection.
7. Has an active severe acute respiratory syndrome coronavirus 2 infection.
8. Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab.
9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site.
10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study.
11. Prior treatment with HER2-targeted therapy (Cohort 1 only).
12. Has a history of trauma or major surgery
13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to enrollment.
14. Was treated in a prior clinical study of zanidatamab or received zanidatamab at any time prior to the current study.
15. Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations.
16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion.
17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.

Contacts and Locations

Study Contact

Clinical Trial Disclosure & Transparency

CONTACT

215-832-3750

ClinicalTrialDisclosure@JazzPharma.com

Study Locations (Sites)

Sarah Cannon Research Institute at Florida Cancer Specialists

Orlando, Florida, 32837

United States

SCRI Oncology Partners

Nashville, Tennessee, 37203

United States

Collaborators and Investigators

Sponsor: Jazz Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-31

Study Completion Date2027-12-31

Study Record Updates

Study Start Date2024-12-31

Study Completion Date2027-12-31

Terms related to this study

Keywords Provided by Researchers

JZP598
ZW25
HER2 IHC 3+ Overexpression Solid Tumors

Additional Relevant MeSH Terms

Breast Cancer
Gastric Cancer
Esophageal Cancer
Gastroesophageal Cancer
Colorectal Cancer
Endometrial Cancer
Non-small Cell Lung Cancer
Ovarian Cancer
Urothelial Carcinoma
Salivary Gland Cancer
Pancreatic Cancer
HER-2 Protein Overexpression